Investment Thesis
Early-stage medical device company with exceptional gross margins (95.7%) and explosive revenue growth (814% YoY), but unsustainable cash burn (-$13.6M annually) against minimal revenue ($1.2M) creates critical 11-month funding runway. Severe operating losses (-986.6% margin) and dilution risk from inevitable capital raise outweigh early commercialization promise.
Strengths
- Exceptional 95.7% gross margin indicates superior product economics and pricing power
- Extraordinary 814% YoY revenue growth demonstrates strong early market adoption and commercial traction
- Fortress balance sheet with $12M cash position and minimal debt (0.05x Debt/Equity), providing flexibility
Risks
- Critical cash runway of only ~11 months given -$13.6M annual operating cash burn rate against $12M cash balance
- Massive operating expense structure: -$12.2M operating loss on just $1.2M revenue indicates severe cost inefficiency unrelative to revenue scale
- Pre-profitability stage with no visible path to breakeven requires substantial dilutive capital raise, eroding shareholder value
Key Metrics to Watch
- Quarterly revenue growth rate sustainability and deceleration trajectory
- Monthly cash burn trend and updated runway calculation for urgency of funding
- Operating expense ratio to revenue and progress toward gross margin leverage into operating profitability
Financial Metrics
Revenue
1.2M
Net Income
-12.2M
EPS (Diluted)
$-0.58
Free Cash Flow
-13.6M
Total Assets
14.2M
Cash
12.0M
Profitability Ratios
Gross Margin
95.7%
Operating Margin
-986.6%
Net Margin
-984.6%
ROE
-116.6%
ROA
-85.8%
FCF Margin
-1,102.0%
Balance Sheet & Liquidity
Current Ratio
3.63x
Quick Ratio
3.61x
Debt/Equity
0.05x
Debt/Assets
26.4%
Interest Coverage
-676.39x
Long-term Debt
525.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-11T14:57:27.853466 |
Data as of: 2025-12-31 |
Powered by Claude AI